Solid operator, TAM narrative compelling, but execution risk on margin sustainability

YoY figures unverified for public reporting (first listed quarter Nov 2025). Claimed vs. prior proforma private FY26 Q1. QoQ shows revenue +7.9%, PAT +12.2%—much slower.

Consolidated EBITDA (India ₹236Cr + Int'l ₹127Cr) = ₹363Cr. Blended margin 13.3%. Falls well short of 25% steady-state guidance. Claim appears to reference proforma comparisons.

Both figures stated in call. Net new stores 116, yet SSSG held firm, proving densification demand-accretive. Claim supported by data.

Intl EBITDA ₹127Cr on ₹1,203Cr revenue = 10.6%. Prior year was ₹42Cr on ₹873Cr = 4.8% approx. Profitability confirmed.

Figures stated. Remote optometry rollout from 168 to 786 is ~4.7x in 9 months. Eye test growth and remote expansion both material.

Peyush clarified ₹250Cr is ONLY ₹30k+ segment, not total progressives. ₹1,500 Cr is Owndays premium segment, not all Owndays. Both are subsegments, claimed correctly but narrowly.

Q1 margin 10.6% (₹127 Cr EBITDA on ₹1,203 Cr revenue), vs 4.8% prior year. Profitability thesis no longer questioned. Remains below India 15.4%, but crossing 10% is material upgrade.

25% steady-state target maintained but 13.3% blended delivered. Management hedged: 'quarterly variance expected'. No formal FY27 guide, but tone shifted to flexibility vs. prior leverage narrative.

Peyush flagged talent/culture/speed as #1 bottleneck (above real estate, product). Tier-2 expansion requires local hiring, training. AI/data engineering talent scarce. Not previously prominent risk.

Management stated 'we can do it profitably' now (previously cost-prohibitive). Largest ever cohort onboarded in Q1. Democratization strategy moving from aspirational to live.

Penetration only 35%, myopia/progressives gaining share, eye tests top funnel. Offset currency via in-house mfg, vendor discounts, backward integration. SSSG held 18% despite density increase.

Tier-2 needs logistics/talent muscle; remote optometry was unlock. Premium = ₹3.5k+ lenses, ₹5k+ frames (Owndays, Meller). ₹500 = India mfg, logistics optimization, omnichannel CAC efficiency.

NPS dip was policy confusion, bounced back. SSG accelerating YoY (18% vs 16%). Talent is #1 constraint; need data/AI engineers. Remote optometry and self-eye test are unlocks.

₹250 Cr is only super-premium, not all progressives. Playbook = eye test + marking + AI design. Brand via authenticity (Virat in Meller ₹50, Blackpink), not above-the-line spend.

Following India playbook (100→300→450): focus eye tests, capex rationalization, margin recovery first. Flywheel unlocks acceleration; Japan getting there; SSG headroom in intl markets.

Majority convert; first-time customers take longer. Unlikely to forecast FY27 full-year margin vs quarter; seasonality in Q1 (sunglasses), YoY improving overall.

Closer to acceleration, tech integration ongoing. Eyewear is neighborhood model everywhere. GeoIQ now mapping intl; pin codes are shareholder storytelling, actual model data-driven.

Remote more consistent than unmonitored optometrist. Use Tango Eye (computer vision) for process scoring + exchange data. Prevent cannibalization via omnichannel (face scan app, brand house).

Unit economics work before launch. Lower price points more margin accretive than higher. Rodenstock = manufacturing + licensing (raw materials + design from brand, made in India).

Strategy by market. Singapore dual-brand success (both coexist, serve different segments). Thailand also dual-brand working. Japan different strategy. Learning as we go.

CEO framed as market-creation play; store additions 455 in 9m, suggesting base case 600+ net adds/year. Implies revenue CAGR but unquantified.

Current 13.3% blended; management hedged: quarterly variance expected due to store opening phasing, seasonality, strategic investments. No near-term lift timeline.

Hyderabad facility supports backward integration (frames, lenses). Capex intensity moderate (~4% of revenue). No full-year guidance.

Blended EBITDA margin 13.3% (India 15.4%, Int'l 10.6%) is half the long-term 25% guidance. Gap not explained by near-term investments alone. If margins do not recover to 20%+ by FY28, thesis breaks.

455 net stores added in 9 months; density 1.5→1.6/pin code. SSSG held 18.3% YoY, but older cohorts may face incremental pressure. At 10,000 stores (3.5x scale), cannibalization could emerge.

Peyush flagged talent/culture/speed as #1 constraint (above real estate, product). Tier-2 expansion requires local hiring, training, retention. Data/AI talent scarce. Risk if hiring cannot keep pace with store expansion.

Remote eye tests now in 786 stores (27% of network), driving volume +42.7%. Accuracy monitored via Tango Eye (process scoring) + customer exchange rates, not independent audits. Risk if accuracy later questioned or regulator scrutinizes.

NPS moderated in Q1 due to social media policy miscommunication. Resolved per Peyush, but signals execution risk on service quality as Tier-2 expansion accelerates. Service consistency across 2,900+ stores under pressure.

Only 16 net stores added internationally in Q1 despite 38% revenue growth (SSG doing heavy lifting). Tech integration 'maybe not this year.' If delayed, international remains low-store-count, high-SSG business. Margin leverage from scale deferred.

Lenskart's moat is scale, omnichannel, data (GeoIQ, Tango), and acquired brands (Owndays, Meller). Traditional opticians have installed base and relationships. Online D2C (Warby Parker-style) could emerge. If competitor copies remote optometry + AI eye test, competitive moat erodes.